The clinical performance is complex and often involves multiple systemic burdens. Early identification and standardized diagnosis are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can assist in linking teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of genetic myeloma concomitant transmission defects require individual development, usually including multidimensional management, including pharmacotherapy, rehabilitation interventions, and regular follow-up. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many autoimmune and rheumatic immune diseases that have previously been difficult to treat have been significantly improved.
Treatment needs to be closely monitored for efficacy and adverse reactions, adapted to timely regimens according to changes in the condition. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of defects in the transmission of hereditary myeloma. The platform serves China International Medical Service System, a team of domestic and foreign experts with authority in the field of autoimmune and rheumatic immunity, to provide the following services to patients: 1.
2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.